1 / 25

Pharmaceutical Issues

Pharmaceutical Issues. Rao Vishnuvajjala, Ph.D Chief, Pharmaceutical Resources Branch (PRB). Requirements. Chemical Substance to Human Drug Standardize Processes to Assure Safety & Consistency Identity Quality Purity Strength. Operational Areas. Bulk Drug Synthesis

cain
Télécharger la présentation

Pharmaceutical Issues

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Pharmaceutical Issues Rao Vishnuvajjala, Ph.D Chief, Pharmaceutical Resources Branch (PRB)

  2. Requirements Chemical Substance to Human Drug • Standardize Processes to Assure Safety & Consistency • Identity • Quality • Purity • Strength

  3. Operational Areas • Bulk Drug Synthesis • Analytical Development & Validation • Formulation Research & Development • Clinical Dosage Form Manufacture • Shelf Life Monitoring

  4. Research Contracts • Solicitation - RFP Process • Select Organizations With Expertise • Selected by Open Competition • Contracts Awarded for Five Year Periods

  5. Bulk Drugs ASI, Starks, Alchem Analytical MRI, RTI, SRI Formulations Arizona, Kansas, Utah Manufacture Ben Venue Labs, Iowa Shelf Life US Bio/Medimmune Contractors

  6. Recompetitions • Shelf Life Contract • Analytical Contracts • Formulation R& D Contracts • Dosage Form Manufacture Contracts • http://rcb.nci.nih.gov/appl/rfp/

  7. PRB Staff • Shanker Gupta, Ph.D. • Paul Liu, Ph.D. • Ken Snader, Ph. D. • Vacant (Pharmaceutical Chemist) • http://reports.cit.nih.gov/jobsnih/advacsearch.asp

  8. Bulk Drug Synthesis • Develop Synthetic Route • Purification Process • Scale Up of Reactions • Improve Purification Process & Optimize Yield • Develop GMP Procedures • Prepare Large Batches & Provide Documentation • Prepare Reference Standard

  9. Synthetic Projects SarCNU DB-67 CDDO RH-1

  10. Synthetic Projects Phortress CAI 9-Nitropaullone XK-469R

  11. Synthetic Projects PT-523 5-Azacytidine BPU 17-AAG

  12. Analytical Chemistry (General) • Identity of Molecular Structure • IR, NMR, MS, EA, etc… • Develop Purity Tests • HPLC, GC, TLC, etc… • Test for Other Impurities • Moisture (K-F), Residual Solvents (GC) • ROI, Heavy Metals

  13. Analytical Chemistry (Batches) • Confirm Identity • Determine Purity & Potency (Assay) • Levels of Other Impurities • Methods Validation • Establish Release Specifications • Stability of Bulk Drug Substance

  14. Typical Specifications • Bulk Drug Substance • Purity: > 98% • Impurities: NMT 2% Total; 0.5% Single • Residual Solvents: NMT 0.1 to 0.2% • Residue on Ignition: NMT 0.1%

  15. Formulation Research (Goals) Provide Solution of Active Drug for iv Use. Solution Components Should Be: • Compatible with Blood • Non-Toxic to Blood Components and Host • Should be Free of Particulates • Isotonic • Suitable for Sterilization • Approved, USP/NF, Where Possible • Proven Safety Record

  16. Solubility Options • Salt Formation • Co-solvents: DMSO, EtOH, PG, PEG,etc. • Surfactants: Cremophor EL, Tween, etc. • Emulsions: O/W, EPL, Pluronics, Etc.. • Complexes: HPCD, SBE-4. • Pro-drugs • Liposomes

  17. Stability Options • Hydrolysis pH adjustment, Lyophilization • Oxidation Anti-oxidants • Photochemical Amber Vials, Boxes • Thermal Storage Temp.

  18. Formulation Research • Defines • Components & Composition • Type of Dosage Form • Container/Closure System • Storage Conditions • Reconstitution Vehicles (Lyo products) • Useable Periods • Stability and Compatibility with Devices

  19. Drug Product Manufacturing • Manufacture of Pilot Batches • Accelerated Stability Testing • Raw Material Qualifications • Bio-load Determination • Microbial Validations • Preparation of PIP • Preparation of Master Batch Record • Design and Printing of Labels

  20. Drug Product Manufacturing • Follow SOPs, GMP and QC Procedures • Prepare Drug Product, In-process Testing • Sterilize and Lyophilize, as applicable • Quality Control, Including Chemical & Microbial Testing • Establish Product Release Specifications • QC Release, Labeling, and Packaging

  21. Drug Product Manufacturing • QC/QA Review of Procedures and Batch Record • Send Clinical Batches to NCI Repository • Provide Documentation for IND • Special Studies: • Solution Stability and Compatibility with Infusion Solutions and Devices ( pumps, bags, iv sets, etc…)

  22. Shelf Life Monitoring • Develop Storage & Stability Testing Protocols • Monitor Stability on Established Time Schedule • Promptly Recall Batches that fall Outside Established Specifications • Each Clinical Lot is Monitored for Stability

  23. Our next speaker is: Dr. Joseph Tomaszewski Toxicology & Pharmacology Branch Developmental Therapeutics Program

More Related